M1A.2590 Drug-induced chronic gout, unspecified hip, without tophus (tophi)

Name of the Condition

• Drug-Induced Chronic Gout, Unspecified Hip, Without Tophus (Tophi)

Summary

Drug-induced chronic gout, unspecified hip, without tophus is a form of arthritis affecting the hip joint, resulting from prolonged elevated uric acid levels due to medication use. It leads to recurrent joint inflammation and potential tissue damage, characterized by persistent symptoms without the presence of tophi (urate crystal deposits) in this stage.

Causes

This condition arises from medications that interfere with uric acid metabolism or excretion, causing accumulation in the blood. Over time, urate crystals deposit in the hip joint and surrounding tissues, triggering inflammation. Common culprits include diuretics, low-dose aspirin, and certain chemotherapy agents.

Risk Factors

• Use of medications that increase uric acid levels (e.g., diuretics, low-dose aspirin)
• Prolonged exposure to urate-raising drugs
• Pre-existing hyperuricemia or gout history
• Renal impairment affecting drug clearance

Symptoms

• Recurrent episodes of intense hip pain, often with swelling and redness
• Persistent warmth and tenderness in the affected hip
• Stiffness and limited range of motion in the hip
• Flare-ups triggered by stress, diet, or illness

Diagnosis

Diagnosis involves clinical evaluation, laboratory tests, and imaging. Blood tests assess uric acid levels, while joint fluid analysis may detect urate crystals. Imaging such as X-rays or ultrasound can reveal joint damage or crystal deposits. The absence of tophi is confirmed through physical examination and imaging.

Treatment Options

Treatment focuses on managing uric acid levels and reducing inflammation. Medications like urate-lowering agents (e.g., allopurinol) may be prescribed to prevent crystal formation. Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids can alleviate acute flare-ups. Lifestyle modifications, including dietary changes and hydration, support overall management.

Prognosis and Follow-Up

With proper management, symptoms can be controlled, and joint damage may be minimized. Regular follow-up is essential to monitor uric acid levels and adjust treatment as needed. Long-term adherence to therapy improves outcomes and reduces recurrence risk.

Complications

Untreated or poorly managed cases may lead to chronic joint damage, persistent pain, and reduced mobility. In rare instances, severe inflammation could contribute to joint deformity or functional impairment.

Lifestyle & Prevention

• Avoid medications known to elevate uric acid levels when possible.
• Maintain a balanced diet low in purines (e.g., limit red meat, seafood).
• Stay hydrated to support uric acid excretion.
• Limit alcohol consumption, particularly beer and spirits.

When to Seek Professional Help

Seek care if experiencing severe or persistent hip pain, swelling, or stiffness. Prompt evaluation is recommended if symptoms worsen or new joint issues arise, as early intervention can prevent complications.

Tips for Medical Coders

Use this code for cases of drug-induced chronic gout affecting the hip joint without tophi. Ensure documentation specifies the absence of tophi and confirms the hip as the affected site. Verify that the condition is chronic and drug-induced, with no tophaceous deposits present.